Journals / Turkish Journal of Gastroenterology / 2002 / Cilt: 13 - Sayı: 2

İdiopatik portal ven kavernöz transformasyonu olan hastalarda etiolojik veya yardımcı faktör olarak antikardiolipin antikorlar ve lipoprotein (a)

Antiphospholipid antibodies and lipoprotein (a) as etiologic or contributory factors in patients with idiopathic cavernous transformation of portal vein

Pages
89–93
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is suggested that these factors should be evaluated carefully in patients with idiopathic cavernous transformation of the portal vein.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims Antiphospholipid antibodies consisting of anticardiolipin antibodies and lupus anticoagulant are strongly associated with thrombosis in adult patients.
📊
Key Findings & Data:Methods: Twenty seven patients with idiopathic cavernous transformation of the portal vein (Group 1) seen at Hacettepe University Hospital were identified and prospectively studied.
💡
Conclusion & Impact:It is suggested that these factors should be evaluated carefully in patients with idiopathic cavernous transformation of the portal vein.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Portal ven · Tromboz · Lupus pıhtılaşma inhibitörü

Abstract

Background/aims Antiphospholipid antibodies consisting of anticardiolipin antibodies and lupus anticoagulant are strongly associated with thrombosis in adult patients. It is also well known that there is a close relationship between antiphospholipid antibodies and lipoprotein (a) in thrombous formation. The aim of this study was to determine whether antiphospholipid antibodies and lipoprotein (a) have any effect on the formation of thrombosis in the portal vein of patients with 'idiopathic' cavernous transformation of the portal vein. Methods: Twenty seven patients with idiopathic cavernous transformation of the portal vein (Group 1) seen at Hacettepe University Hospital were identified and prospectively studied. All were investigated for antiphospholipid antibodies and lipoprotein (a). Anticardiolipin antibodies, lupus anticoagulant and lipoprotein (a) were measured using commercially available kits. The findings of these 27 patients were compared with those of 20 healthy control subjects (Group 2). Results: Anticardiolipin antibodies, especially ACA Ig G and lipoprotein (a) levels were found to be higher than of healthy controls and statistically significant differences were documented in two of these parameters, which seems to play an important role in thrombous formation in the portal vein. There was no correlation for lupus anticoagulant between the two groups. Conclusions: Anticardiolipin antibodies and lipoprotein (a) are strongly associated with thrombosis in the portal vein, producing a favorable medium for and acting as contributory fac-tors in thrombous formation. It is suggested that these factors should be evaluated carefully in patients with idiopathic cavernous transformation of the portal vein.

Özet

Amaç: Antikardiolipin antikorları ve Lupus antikoagülanını bünyesinde barındıran antifosfolipid antikorlar erişkin yaştaki trombozlarla yakından ilişkilidir. Ayrıca trombus oluşumunda antifosfolipid antikorlar ile lipoprotein (a) arasında da yakın bir ilişki vardır. Bu çalışmada "idiopatik"portal ven kavernöz transformasyonu olan vakalarda, portal vende trombus gelişimine antifosfolipid antikorlar ve lipoprotein (a) nın etkisinin olup olmadığını araştırmayı amaçladık. Yöntem: Bu amaçla, Hacettepe Üniversitesi hastanesi tarafından takip edilen ve idiopatik portal ven kavernöz transformasyonu tanısı alan 27 hasta (Grup 1) çalışmaya alındı. Hastaların tümü antifosfolipid antikorlar ve lipoprotein (a) yönünden incelendi. Antikardiolipin antikorları, lupus antikoagülanı ve lipoprotein (a) ölçümleri hazır ticari kitler kullanılarak yapıldı. Hasta grubundan elde edilen bulgular, 20 kişilik sağlıklı kontrol (Grup 2) grubundan elde edilen bulgularla karşılaştırıldı. Bulgular: Hasta grubunda antikardiolipin antikorları, özelikle de antikardiolipin antikorları Ig G ve lipoprotein (a) düzeyleri kontrol grubuna oranla yüksek olarak ölçüldü. Bu iki parametre bakımından iki grup arasında istatistiksel olarak fark saptandı. Bu bulgu, antikardiolipin antikorları Ig G ve lipoprotein (a)'nın portal vende trombus gelişiminde önemli rolü olabileceğini göstermektedir. Lupus antikoagülanı bakımından iki grup arasında farklılık saptanmadı. Sonuç: Antikardiolipin antikorları ve lipoprotein (a) portal vende trombus gelişimi ile yakından ilişkilidir. Bunlar, gerek tromboz için uygun ortamı hazırlayarak gerekse de yardımcı faktör olarak portal vende tromboz gelişimine neden olmaktadırlar. Bu çalışmada, portal vende tromboz gelişimi ile antikardiolipin antikorları Ig G ve lipoprotein (a) düzeyleri arasında bir korelasyon olduğu ve bu faktörlerin kombinasyonlarında da tromboz insidansının arttığı saptanmıştır. Dolayısıyla bu faktörler idiopatik portal ven kavernöz transformasyonu olan hastalarda dikkatli bir şekilde araştırılmalıdır

🔖

Cite This Article

EGESEL, T., ÜNSAL, İ., BAYRAKTAR, Y. (2002). İdiopatik portal ven kavernöz transformasyonu olan hastalarda etiolojik veya yardımcı faktör olarak antikardiolipin antikorlar ve lipoprotein (a). Turkish Journal of Gastroenterology, Cilt: 13 - Sayı: 2, 89–93. https://ajindex.com/articles/410438

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Balfour GW, Stewart TG. Case of enlarged spleen complicated with ascites, both depending upon varicose dilatation and thrombosis of portal vein. Edinburgh Med J 1869; 14: 589-8
  2. Webb LJ, Sherlock S. The etiology, presentation and natural history of extrahepatic portal venous obstruction. QJM 1979; 192: 627-39
  3. Oishi N, Swisher SN, Stromont JM, et al. Portal hypertension in myeloid metaplasia. Arch Surg 1960; 81: 98-104
  4. Scherlock S: Disease of the liver and biliary system. Scherlock S. ed. The portal venous system portal hypertension
  5. Ed. London: Wm Cloud Ltd: 1989:151
  6. Bick RL. Hypercoagulability and Thrombosis. In: Common bleeding and clotting disorders. Medical Clinics of North America 1994; 78: 635-65
  7. Ordi RJ, Perez PP, Monasterio J. Clinical and therapeutic aspects associated to phospholipid binding antibodies (lupus anticoagulant and anticardiolipin antibodies). Hemostasis 1994; 24: 165-74
  8. Yamazaki M, Asakura H, Jokaji H, et al. Plasma levels of lipoprotein (a) are elevated in patients with the antiphospholipid antibody syndrome. Thromb Haemost 1994; 71: 424-7
  9. Dahlen GH, Guyton JR, Attar M, et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary arterydisease documented by angiography. Circulation 1986; 74: 2540-4
  10. Edelberg JM, Pizzo SV. Lipoprotein (a) inhibits plasminogen activation in a template-dependent manner. Blood Coagulat Fibrinol 1991; 2: 756-64
  11. Harris NN, Asherson RA, Gharavi AE, et al. Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody. Br J Haematol 1985; 59: 227-30
  12. Yamazaki M. Lupus anticoagulant. Rinshoui 1992; 18: 98- 103
  13. De Castellarnau C, Vila CL, Sancho MJ. Lupus anticoagulant, recurrent abortion, and prostacyclin production by cultured smooth muscle cells. Lancet 1983; 2: 1137
  14. Triplett DA. Developments in antiphospholipid-protein antibadies In: Recent Advances in Blood Coagulation. Ed: Poller L, Ludlam CA
  15. Ed Saunders, W.B. Company: 1996:19
  16. Derksen RHWM, De Groot G, Kater L, et all. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993; 52: 689-92
  17. Gibson J, Nelson M, Brown R, et al. Autoantibodies to thrombomodulin: development of an enzyme immunoassay and a survey of their frequency in patients with the lupus anticoagulant. Thromb Haemost 1992; 67: 507-9
  18. Marciniak E, Romond EH. Impaired c